ストックスクリーナーアプリを入手
11.41
0.09%
0.03
前日終値:
$11.38
開ける：
$11.53
24時間の取引高:
7,419
Relative Volume:
0.07
時価総額：
$171.97M
収益：
$1.80M
当期純損益:
$1.76B
株価収益率:
0.0961
EPS:
118.674
ネットキャッシュフロー:
$-149.23M
1週間 パフォーマンス:
-3.39%
1か月 パフォーマンス:
-20.63%
6か月 パフォーマンス:
-27.91%
1年 パフォーマンス:
-66.60%
1日の値動き範囲:
$11.40
$11.91
1週間の範囲:
$11.22
$12.04
52週間の値動き範囲:
$10.80
$34.75
Inhibrx Biosciences Inc Stock (INBX) Company Profile
名前
Inhibrx Biosciences Inc
セクター
電話
(858) 795-4220
住所
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
INBX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
11.54 | 171.97M | 1.80M | 1.76B | -149.23M | 118.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.46 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.23 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.32 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.66 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.43 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-23 | 開始されました | JMP Securities | Mkt Perform |
| 2024-01-23 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | 開始されました | SMBC Nikko | Outperform |
| 2021-09-21 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-09-14 | 開始されました | Credit Suisse | Outperform |
| 2020-09-14 | 開始されました | Evercore ISI | Outperform |
すべてを表示
Inhibrx Biosciences Inc (INBX) 最新ニュース
(INBX) On The My Stocks Page - news.stocktradersdaily.com
Inhibrx Biosciences reshuffles leadership, appoints new CSO and President By Investing.com - Investing.com South Africa
Inhibrx Biosciences reshuffles leadership, appoints new CSO and President - Investing.com India
Inhibrx Biosciences Announces Departure Of CSO And Appointments Of New CSO And President - TradingView
Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President - PR Newswire
Major Leadership Shake-up at Inhibrx: New CSO Takes Helm After $2.2B Sanofi Victory - Stock Titan
How the (INBX) price action is used to our Advantage - news.stocktradersdaily.com
JMP maintains Market Perform on Inhibrx stock post-earnings - Investing.com India
Inhibrx Biosciences, Inc. SEC 10-K Report - TradingView
Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Yahoo
Inhibrx Cancer Drug Shows Complete Response as Company Posts $1.7B Annual Profit - Stock Titan
Long Term Trading Analysis for (INBX) - Stock Traders Daily
When (INBX) Moves Investors should Listen - Stock Traders Daily
A closer look at Inhibrx Biosciences Inc (INBX)’s stock price trends - US Post News
When the Price of (INBX) Talks, People Listen - Stock Traders Daily
BlackRock, Inc. Increases Stake in Inhibrx Biosciences Inc. - GuruFocus.com
(INBX) Trading Signals - Stock Traders Daily
Inhibrx reports promising ozekibart trial results - MSN
Inhibrx's SWOT analysis: oncology biotech stock faces pivotal year ahead - MSN
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 - GuruFocus.com
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer – Company Announcement - Financial Times
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer - PR Newswire
How to Take Advantage of moves in (INBX) - Stock Traders Daily
Inhibrx Biosciences enters $150M loan facility - MSN
Regeneron, Illumina invest in Truveta; Inhibrx Bio’s $150M loan - Endpoints News
Inhibrx Biosciences, Inc. Announces Loan Agreement with Oxford Finance LLC - Marketscreener.com
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance - StreetInsider.com
(INBX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
How To Trade (INBX) - Stock Traders Daily
Inhibrx's SWOT analysis: biotech stock faces pivotal year amid clinical trials - Investing.com India
(INBX) Trading Report - Stock Traders Daily
Inhibrx Biosciences' SWOT analysis: oncology firm's stock faces pivotal year By Investing.com - Investing.com Nigeria
Inhibrx Biosciences' SWOT analysis: oncology firm's stock faces pivotal year - Investing.com
2024’s Busiest Dealmakers: Novartis Laps The Field, While Lilly, Sanofi Keep Busy - News & Insights
Inhibrx Biosciences director Jon Faiz Kayyem buys $1.52m in stock - Investing.com Nigeria
Trend Tracker for (INBX) - Stock Traders Daily
The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the shares - Yahoo Finance
institutional investors of Inhibrx Biosciences, Inc. (NASDAQ:INBX) must be disappointed after last week's 15% drop - Simply Wall St
Perceptive Advisors LLC Bolsters Stake in Inhibrx Biosciences Inc - GuruFocus.com
Inhibrx Biosciences Inc (INBX) Quarterly 10-Q Report - Quartzy
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - PR Newswire
Inhibrx Biosciences Inc. (INBX) Quarterly 10-Q Report - Quartzy
Wilson Sonsini Knocks Out Claims Against Inhibrx Biosciences in Trade Secrets Verdict - Law.com
Inhibrx Biosciences’ Trade Secret Case - Global Legal Chronicle
Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha
Inhibrx Biosciences Inc (INBX) 財務データ
収益
当期純利益
現金流量
EPS
Inhibrx Biosciences Inc (INBX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Kayyem Jon Faiz | Director |
Nov 20 '24 |
Buy |
14.19 |
37,500 |
532,204 |
69,843 |
| Lappe Mark | Chief Executive Officer |
Sep 12 '24 |
Buy |
15.05 |
26,963 |
405,793 |
692,511 |
| Lappe Mark | Chief Executive Officer |
Sep 16 '24 |
Buy |
17.13 |
13,037 |
223,324 |
705,548 |
| Vuori Kristiina MD | Director |
Sep 11 '24 |
Buy |
15.07 |
6,457 |
97,307 |
13,776 |
| Vuori Kristiina MD | Director |
Sep 10 '24 |
Buy |
15.00 |
179 |
2,685 |
7,319 |
| Lappe Mark | Chief Executive Officer |
Sep 06 '24 |
Buy |
15.29 |
26,000 |
397,540 |
647,548 |
| Lappe Mark | Chief Executive Officer |
Sep 09 '24 |
Buy |
15.21 |
9,500 |
144,495 |
657,048 |
| Lappe Mark | Chief Executive Officer |
Sep 10 '24 |
Buy |
15.19 |
8,500 |
129,115 |
665,548 |
| Lappe Mark | Chief Executive Officer |
Sep 03 '24 |
Buy |
15.81 |
20,000 |
316,263 |
165,000 |
| Lappe Mark | Chief Executive Officer |
Aug 29 '24 |
Buy |
14.03 |
10,000 |
140,300 |
135,000 |
1.75%
2.22%
大文字化:
|
ボリューム (24 時間):